|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Thereafter, we investigated GLUD2 relevance in cancer cell behavior by GLUD2 overexpression and silencing in two different human GBM cell lines.
|
30314897 |
2018 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
To reveal the most prevalent variant alleles, we overlaid our findings with cancer- and population-based datasets and validated a subset of novel variants of cancer-related genes: ESRP2, GBP1, TPP1, MAD2L1BP, GLUD2 and SLC30A8.
|
23884293 |
2013 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Glutamate production from ammonia via glutamate dehydrogenase 2 activity supports cancer cell proliferation under glutamine depletion.
|
29146184 |
2018 |
|
Parkinson Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
With regard to hGDH2, a rare T1492G variation in the GLUD2 gene, resulting in substitution of Ala for Ser445 in the regulatory domain of hGDH2, interacts significantly with Parkinson's disease (PD) onset.
|
23463419 |
2013 |
|
Parkinson Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As there is evidence for deregulation of glutamate metabolism in degenerative neurologic disorders, we sequenced GLUD1 and GLUD2 genes in neurologic patients and found that a rare T1492G variation in GLUD2 that results in substitution of Ala for Ser445 in the regulatory domain of hGDH2 interacted significantly with Parkinson's disease (PD) onset.
|
21420458 |
2011 |
|
Parkinson Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Individuals hemizygous for this GLUD2 coding change that results in substitution of Ala for Ser445 in the regulatory domain of hGDH2 developed PD 6-13 years earlier than did subjects with other genotypes in two independent Greek PD groups and one North American PD cohort.
|
19826450 |
2010 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Thereafter, we investigated GLUD2 relevance in cancer cell behavior by GLUD2 overexpression and silencing in two different human GBM cell lines.
|
30314897 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Glutamate production from ammonia via glutamate dehydrogenase 2 activity supports cancer cell proliferation under glutamine depletion.
|
29146184 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
To reveal the most prevalent variant alleles, we overlaid our findings with cancer- and population-based datasets and validated a subset of novel variants of cancer-related genes: ESRP2, GBP1, TPP1, MAD2L1BP, GLUD2 and SLC30A8.
|
23884293 |
2013 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Results from this study raise the possibility that GDH2-specific inhibition may be a viable therapeutic strategy for gliomas with <i>IDH</i> mutations.<b>Significance:</b> These findings show that the homonid-specific brain enzyme GDH2 may be essential to mitigate metabolic liabilities created by IDH1 mutations in glioma, with possible implications to leverage its therapeutic management by IDH1 inhibitors.<i></i>.
|
29097607 |
2018 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further, we report that glutamate, a substrate of GLUD2 and a neurotransmitter abundant in mammalian neocortex, can support growth of glioma progenitor cells irrespective of IDH1 mutation status.
|
25225364 |
2014 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Also, the anaplerotic function of GDH1 and GDH2 is currently under sharp focus as this relates to the biology of glial tumors and other neoplasias.
|
27422263 |
2017 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Strikingly, introduction of GLUD2 into murine glioma progenitor cells reverses deleterious effects of IDH1 mutation on metabolic flux and tumor growth.
|
25225364 |
2014 |
|
Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The GluD2 receptor is a puzzling member of the iGluR family: It is involved in synaptic plasticity, plays a role in human diseases, e.g. ataxia, binds glycine and D-serine with low affinity, yet no ligand has been discovered so far that can activate its ion channel.
|
28387240 |
2017 |
|
Cerebellar Ataxia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The GluD2 receptor is a puzzling member of the iGluR family: It is involved in synaptic plasticity, plays a role in human diseases, e.g. ataxia, binds glycine and D-serine with low affinity, yet no ligand has been discovered so far that can activate its ion channel.
|
28387240 |
2017 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLUD2 also protected the host mouse from developing diabetes with advancing age.
|
31400387 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
GLUD2 also protected the host mouse from developing diabetes with advancing age.
|
31400387 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the anti-GluN2B and anti-GluD2 antibodies may be associated with myoclonic atonic epileptic seizures and chronic cerebellitis.
|
28246062 |
2017 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GLUD2 expression was found associated to the histopathological classification, prognosis and survival of GBM patients.
|
30314897 |
2018 |
|
Infectious Mononucleosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The GLUD1 but not the GLUD2 gene expression pattern is different between the PBMC of IM and B-CLL patients.
|
19683518 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The GLUD1 but not the GLUD2 gene expression pattern is different between the PBMC of IM and B-CLL patients.
|
19683518 |
2009 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Antibodies to GluD2 were identified in 14/16 (87%) OMAS samples, compared with 5/139 (5%) pediatric and 1/38 (2.6%) adult serum controls (<i>p</i> < 0.0001), and in 2/4 sera from patients with neuroblastoma without neurologic features.
|
30045961 |
2018 |
|
Rett Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The intronless gene GLUD2, located in Xq25 and expressed in neuronal and testicular tissues, is involved in the metabolism of glutamate, a neurotransmitter reported to be elevated in the spinal fluid of RTT individuals.
|
9674910 |
1998 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on the known function of its paralog GluD2 in cerebellum, we searched for a role of GluD1 in slow glutamatergic transmission mediated by metabotropic receptor mGlu1 in midbrain dopamine neurons, whose dysfunction is a hallmark of schizophrenia.
|
28696429 |
2018 |
|
Cerebral atrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Homozygous GRID2 missense mutation predicts a shift in the D-serine binding domain of GluD2 in a case with generalized brain atrophy and unusual clinical features.
|
29207948 |
2017 |